Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.

Trial Details

NCT ID
NCT05072600
Phase
PHASE2
Sponsor
Peking University First Hospital
Status
RECRUITING
Cancer Type
Muscle-Invasive Bladder Cancer
Interventions
  • Pembrolizumab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent.
  • Based on AJCC 8th edition: stage cT2-4N0M0,Urothelial carcinoma \>50% and
  • Requires definitive local therapy
  • Has received maximum TURBT followed by tri-modality therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Muscle-Invasive Bladder Cancer Trials on Trialify →